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resumo 
 
 
Demência é uma síndrome clínica caracterizada pelo declínio progressivo das 
capacidades cognitivas, estando a tornar-se cada vez mais comum, devido ao 
envelhecimento da população mundial. Prevê-se que o número de doentes com 
demência aumente em cerca de 30 milhões nos próximos 15 anos, 
representando grandes gastos para os sistemas de saúde e sociais. Existem 
vários tipos de demência, sendo que a Doença de Alzheimer (DA) é a mais 
comum, afetando entre 20 a 30 milhões de pessoas em todo o mundo, das quais 
90.000 são portuguesas. A compreensão das características genéticas e 
moleculares associadas a esta doença pode constituir um meio para descobrir 
novos métodos de diagnóstico e tratamento. A maior parte dos casos de 
Alzheimer tem início tardio, afetando indivíduos com 65 ou mais anos de idade. 
Até recentemente apenas o gene que codifica a Apolipoproteína E (APOE) foi 
associado com esta forma de DA. No entanto, estudos recentes de associação 
genómica identificaram o gene BIN1 como sendo o loci de risco associado ao 
Alzheimer tardio mais significativo depois do APOE. Além disso, vários SNPs do 
BIN1 foram associados a este tipo de Alzheimer, sendo que o polimorfismo 
rs744373 foi proposto como um dos mais relevantes para a DA. Dado que os 
SNPs mais significativos podem variar de população para população, o objetivo 
principal deste trabalho foi avaliar se o polimorfismo rs744373 do gene BIN1 
pode ser associado a um aumento do risco de desenvolver DA, numa população 
portuguesa do distrito de Aveiro, que pertence a um estudo transversal baseado 
em populações, realizado na Universidade de Aveiro. Analisámos 63 indivíduos 
Portugueses, sendo 32 doentes e 31 controlos. Neste estudo conseguimos 
observar que, de uma forma geral, o alelo A é o mais frequente e que o alelo G 
(alelo de risco) foi o menos frequente, numa razão de 3:1. Não conseguimos 
encontrar uma forte evidência de associação entre o rs744373 e o risco de 
desenvolver DA (Razão de probabilidade [RP] = 0.733 , valor p = 0.464), o que 
está de acordo com estudos previamente publicados. Não foi detetada 
significância estatística entre o rs744373 e portadores do alelo APOE-Ԑ4 (valor 
p = 0.467) ou indivíduos com demência (CDR≥1) (valor p = 0.269). Foi detetada 
uma associação entre o alelo de risco do polimorfismo de estudo e a presença 
de Diabetes Mellitus (RP = 6.60, valor-p = 0.035). No entanto, como a nossa 
amostra era pequena, deve ser feito um novo estudo para avaliar se este 
resultado pode ser generalizado para a população Portuguesa. 
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abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dementia is a clinical syndrome characterized by a progressive decline in 
cognitive skills, and is becoming increasingly common, due to the aging of the 
world’s population. It is expected that the number of patients with dementia will 
increase by 30 million in the next 15 years, representing a major factor of costs 
in health care and social systems. There are several types of dementia, and 
Alzheimer’s Disease (AD) is the most common, affecting 20 to 30 million people 
worldwide, of which 90.000 are Portuguese. Understanding the genetic and 
molecular characteristics associated with the disease may constitute a way to 
discover new diagnostic methods and treatments. Most cases of AD are late-
onset (LOAD), affecting individuals with 65 or more years of age. Until recently 
only the Apolipoprotein E gene (APOE) had been associated with this form of 
AD. However, recent genome-wide association studies have identified Bridging 
Integrator 1 (BIN1) as the most significant LOAD-associated risk loci after APOE. 
Furthermore, several SNPs of BIN1 have been associated to this type of AD and 
rs744373 was proposed to be one of the most relevant for AD. Since the most 
significant SNP may vary from population to population, the main aim of this work 
was to evaluate if BIN1 polymorphism rs744373 can be associated with the risk 
of AD in a Portuguese population from the Aveiro district, belonging to a cross-
sectional population-based study performed in Aveiro University. We analysed 
63 Portuguese individuals comprising 32 cases and 31 controls. In this study we 
could observe that, overall, allele A was the most frequent and allele G (risk 
allele) was the least frequent, in a ratio of 3:1. We didn’t find strong evidence of 
association for rs744373 with the AD risk (odds ratio [OR] = 0.733 , p-value = 
0.464), which is in agreement with some previous published studies. No 
statistical significance was detected between rs744373 and APOE-Ԑ4 carriers 
(p-value = 0.467) or individuals with dementia (CDR≥1) (p value= 0.269). We 
have detected an association between the risk allele of the study polymorphism 
and the presence of Diabetes Mellitus (odds ratio [OR] = 6.60, p-p-value = 
0.035). Nevertheless, due to our small sample size, a follow-up study is required 
in order to evaluate if this result can be generalized to the Portuguese population. 
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1.1  Dementia 
Dementia is a clinical syndrome usually associated with a group of symptoms and signs that 
culminates with a progressive decline in cognitive skills such as memory, reasoning, attention and 
orientation. It is also characterized by difficulty in language processing, as well as emotional and 
social changes, which might be linked to a state of depression, agitation, hallucinations, 
disinhibition or even insomnia. These changes impair daily life activities 1 like driving, shopping, 
cooking or even attending to personal care, which makes it very hard for patient’s caregivers 2,3.  
With the world’s population rapidly aging, it’s expected that the number of patients with dementia 
will increase 30 million in 15 years 3.   
Depending on the cause, dementia can be reversible (rare and potentially treatable) or 
irreversible, being the first a result of other medical condition and the latter a consequence of a 
neurodegenerative process 3. Either way, most forms of dementia are progressive, becoming more 
severe as the patient ages. However, it is important to highlight that dementia is not part of the 
natural aging process, and so not all old people will develop the symptoms associated to it. Actually, 
although dementia is most frequent after the age of 65, there are cases of patients in the age group 
of 40 to 60 years old that suffer from it 4. For these reasons, it is still unclear if dementia is only an 
aging-related condition or if it tends to develop in older people just because it requires time for the 
pathogenic process to disclose 5.  
There are several types of dementia including Parkinson’s disease 6, dementia with Lewis 
bodies, Frontotemporal dementia and Alzheimer’s Disease (AD) 3. Depending on the dementia, 
although they all tend to have a protracted development, there are two patterns of decline, being 
the first characterized by the late onset of clinical symptoms, while the other presents at an early 
stage.  
Since Alzheimer’s disease is the most common form of age-related dementia, the next 
sections of the present work will be an overview of its molecular and genetic basis.  
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1.2 Alzheimer’s Disease (AD) 
AD is an irreversible and progressive brain disorder, where neurodegeneration is its main 
feature 7,8.  It is characterized by the impairment of several cognitive functions such as memory, 
attention, concentration, language as well as emotional and social changes. In the final stages of 
the disease such symptoms are so severe that the patient has no autonomy, requiring a full-time 
caregiver. In these patients, pneumonia tends to be the leading cause of death 9.  
It is one of the most common diseases in the developed world 10, having an incidence of 
about 20 to 30 million people worldwide 11–13, with an estimated increase of more than 50 million 
people by the year 2040 14. Currently, in Portugal nearly 90.000 individuals suffer from AD leading 
to consider it a major driver of costs in health care and social systems 4. 
The first case of AD was described in 1906 by the German psychiatrist and neuropathologist 
Dr. Alois Alzheimer after whom the disease was named, and it referred to an unusual disease of the 
cerebral cortex of a 51-year-old woman (Auguste D.). This case was an early onset, potentially 
caused by a PSEN2 Volga-German mutation, which led to a progressive cognitive impairment with 
loss of memory and language skills as well as behavioural changes 3,14.  
AD is a multifactorial dementia caused by genetic, epigenetic and environmental factors 
and pathways, which interact among themselves leading to a complex heterogeneity of patient 
populations 5,15. Some of the non-genetic factors that might contribute to the development of the 
disease include infections, hormones, diabetes, smoking or even emotional and social factors 16. 
Although the ultimate risk factor for the appearance of AD is age 3, it has been hypothesized 
that the development of this highly prevalent dementia begins 20 to 30 years before the 
manifestation of the first symptoms 11,17. This first stage of the disease is called Mild Cognitive 
Impairment (MCI) in which people show some cognition deficits in comparison to the average 
individuals of their age, although it does not interfere with their daily lives in a significant way. The 
transition to AD occurs when the neuropathological features are more relevant, such as the spread 
of neurofibrillary tangles (NFTs) beyond the medial temporal lobe in cortex 7,11.  
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Healthy Neuron 
Neuron with NFTs 
1.3 Neuropathological Hallmarks of AD 
Neuropathologically, AD is characterized by atypical protein aggregates 18. The main 
hallmarks of the disease include the presence of senile plaques (SP) and neurofibrillary tangles 
(NFTs), being the first an extracellular accumulation of Amyloid- peptides (A) and the latter a 
intraneuronal accumulation of hyperphosphorylated TAU proteins 19,20 (Figure 1). Neurofilaments 
(NFs) may also play an important role in neurofibrillary pathology and degeneration as they are one 
of the key components of the neuronal cytoskeleton, being the most abundant cytoskeletal protein 
in large myelinated axons 21.  
 
 
 
 
 
 
 
 
Figure 1 – Neuropathological Hallmarks of AD. A - Schematic representation of the neuropathological hallmarks 
of AD. B - Senile Plaques (SP) (seen with Bielschowski silver stain). C – Neurofibrillary tangles (NFTs) (seen with 
Bielschowski silver stain). (Taken from22,23) 
 
Another feature of AD is synapse loss, which may be related to changes in the normal 
functioning of neurons or even due to neuron death. This all culminates in brain atrophy 24,25 of 
specific regions involved in memory and learning processes, namely the limbic system 26,27, 
neocortical regions 28, the basal forebrain 29, and the hippocampus 30, which may partly explain the 
clinical symptoms characteristic of this disease (Figure 2).  
 
 
 
 
 
Figure 2 – Schematic comparison between a cross section of a healthy brain (left) and a brain of a patient with 
AD (right). In the latter it is possible to notice an overall shrinkage, mainly in the cortex and hippocampus, and an 
enlargement of the ventricles. (Taken from 31) 
A C B 
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Senile Plaques are spherical lesions resulting from the build-up of extracellular A, either 
with 40 amino acids (Aβ40) or 42 amino acids (Aβ42), which are produced through the metabolism 
of  Amyloid Precursor Protein (APP) after being sequential cleaved by a group of specific secretases 
(β- and γ-secretases) 3,32.  There is a greater amount of Aβ42 than Aβ40 within the SP due to its higher 
rate of insolubility 33. This neuropathological feature of AD, unlike NFTs, is found mainly in the 
isocortex 33. 
 
1.3.1.1 Amyloid Precursor Protein (APP) 
APP is a ubiquitously expressed type 1 transmembrane glycoprotein composed by 695 to 
770 amino acids, encoded by a single gene located on chromosome 21 (21q21.23) with a length of 
about 240kb and no less than 18 exons 34. Through alternative splicing of exons 7, 8 and 15 of the 
APP mRNA several isoforms are synthesized, predominantly APP695, APP751 and APP770. The 695 
isoform is the only one that lacks the Kunitz Protease Inhibitor (KPI) domain.  
Regarding the structure, APP has three main domains, the Extracellular Domain (EC) which 
includes amino acid residues 1-699 in exons 1-17, the Transmembrane Domain (TM) which is 
composed by residues 700-723 in exons 17 and 18, and the APP Intracellular Domain (AICD) which 
comprises residues 724-770 in exons 17 and 18. The A sequence, which originates the A peptide 
of particular interest in AD, is located in exons 16 and 17 (amino acid residues 672-713), being part 
of both EC and TM 16.  
APP can undergo two different proteolytic pathways: a non-amyloidogenic and an 
amyloidogenic 18. In the non-amyloidogenic pathway, APP starts to suffer the action of α-secretase, 
resulting APPsα (a soluble APP derivative) and a α-carboxyl-terminal fragment (APP-CTFα). This 
latter fragment is subsequently cleaved by -secretase generating a non-toxic peptide (p3) and the 
Amyloid Precursor Protein Intracellular Domain (AICD). In this pathway, as α-secretase action takes 
place in the A peptide sequence, it prevents the subsequent formation of A peptide, whose 
aggregation causes SPs. On the other hand, in the amyloidogenic pathway, APP is first cleaved by 
-secretase, releasing APPs and -carboxyl-terminal fragment (APP-CTF). The APP-CTF is 
afterwards cleaved by -secretase producing A peptide and the AICD 16,35 (Figure 3).  BACE1 and 
BACE2 are the two secretases capable of cleaving APP at the β-site, however it is the first one that 
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acts as a key β-secretase in the brain, since it is the rate-limiting enzyme that starts the Aβ formation 
36. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Schematic diagram of APP processing pathways (not drawn to scale). In the Amyloidogenic pathway 
APP is cleaved by β-Secretase, originating APPsβ and APP-CTFβ. The latter is subsequently cleaved by γ-Secretase 
originating Aβ peptide and AICD fragment. On the other hand, in the Non-Amyloidogenic pathway, APP is first 
cleaved by α-Secretase, giving rise to APPsα and APP-CTFα, being the last cleaved by γ-Secretase, leading to the 
formation of p3 peptide and the AICD fragment. Abbreviations: EC, Extracellular Domain; TM, Transmembrane 
Domain; IC, Intracellular Domain. (Adapted from 16). 
 
1.3.1.2 Amyloid-β peptide (Aβ) 
Amyloid  is a peptide with an approximate length of 40 to 42 amino acids 11, that is 
produced by proteolytic cleavage of APP, first identified in 1984 by Glenner and Wong 37. 
Depending on the -secretase that cleaves APP, a variety of peptides can be generated, 
including A42 and A40. Of these, the A40 is the most abundant variant (about 80%)35 present in 
both healthy brains and brains of people who suffer from AD. On the other hand, A42, which 
aggregates much easier when compared to A40, this is found to be augmented in neuronal cells 
which have suffered mutations in APP or Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes, which 
are associated with Early-Onset Alzheimer’s Disease (EOAD) 38.  
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A is normally secreted in physiological processes, which indicates that it has a physiological 
function 35. Further, it has been discovered through several studies that A is important in 
neurogenesis, producing neuroprotective effects and increasing cell viability when growth factors, 
neurotrophins or excitotoxic conditions are not present 39. It also plays an important role in 
strengthening or weakening synapses, is relevant in synaptic plasticity 40 and memory formation 41. 
In addition, it influences the metal sequestration and antioxidant activity with metals such as 
copper, zinc or iron. The A peptide is also important for the maintenance of homeostasis and so it 
is particularly important in keeping the nervous system healthy 35. The problem with A occurs 
when there is an increase in the A42/A40 ratio, since it eventually contributes to the build-up of 
protein aggregates that accumulate in the brain, leading to neurodegeneration and the 
development of AD 16,35. This is accordingly to amyloid hypothesis, which is well-known and 
accepted among the scientific community.  
In addition, A peptide accumulation might be toxic in a variety of ways, as it can induce 
oxidative stress when synchronized with redox active metals. It can also interact with membranes, 
leading to the formation of pores and consequently contributing to an abnormal flux of ions, 
culminating in neuron death. Finally, Aβ is associated with synaptic dysfunction, telomerase 
dysfunction (through its inhibition) or can even promote apoptosis of neuronal cells 35. 
 
 
NFTs consist of intraneuronal filamentous inclusions primarily constituted by aggregates of 
hyperphosphorylated TAU protein which, in a regular situation, has several roles including the 
stabilization of microtubules and intracellular transport, both axonal and vesicular. Normally TAU 
is a soluble protein, however, after suffering an excessive phosphorylation by several kinases 
eventually becomes insoluble, losing affinity to microtubules and self-associating into paired helical 
filament (PHF) structures and straight filaments, which ultimately evolve into NFTs 42. The PHF 
breadth ranges from 8 to 20nm, with a spacing between crossovers of approximately 80 nm, while 
straight filaments do not have this helical periodicity 43. The presence of NFTs can lead to 
impairment of the normal axonal transport of some components required for function and survival 
of neuronal cells, namely vesicles with neurotransmitters, mitochondria and neurotrophic factors, 
and may result in neurodegeneration 42.  
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NFTs are found in many other neurodegenerative diseases, of which the most predominant 
neuropathologic feature in Progressive Supranuclear Palsy (PSP), corticobasal degeneration (CBD), 
Pick’s disease (PiD), Angyrophilic Grain Disease (AGD) and Dementia Pugilistica (DP), among others 
44. 
1.3.2.1 TAU protein 
TAU is a microtubule-associated protein first discovered and isolated by Weingarten and 
colleagues in 1975 45, having a major role in the assembly and stabilization of microtubules 46. It is 
the major protein associated with the formation of NFTs. 
 
 Expression and isoforms of TAU 
Human TAU is encoded by the Microtubule-Associated Protein TAU gene (MAPT), which is 
located over 100kb on the long arm of chromosome 17, at position 17q21.1, comprising 16 exons 
47. Importantly, exon 1 belongs to the promoter and so, although transcribed it is not translated 48.  
In normal adult human brain, alternative splicing of exon 2 (E2), exon 3 (E3) and exon 10 (E10) 
generates six TAU isoforms ranging from 352 to 441 amino acids in length. The size of those 
isoforms depends on the presence or absence of one or two 29- amino acid insert in the N-terminal, 
which are encoded by E2 and E3, and the inclusion or not of either three (R1, R3 and R4) or four 
(R1-R4) repeat regions in the C-terminal, which are encoded by E10. Therefore isoforms may be 
categorized according to the number of inserts encoded by E2 and E3 (0, 1 or 2), called 0N, 1N or 
2N, and according to the number of repeat domains of the C-terminal encoded by E10 (3 or 4), 
called 3R or 4R 49 (Figure 4). The peripheral nervous system has neurons that often project a very 
long axon with a large diameter, due to the inclusion of a N-terminal sequence encoded by exon 
4a, resulting in the expression of a specific TAU isoform named “big TAU” 50,51. 
Throughout the development of the human brain, TAU isoforms are differentially 
expressed, whereby during the foetal stages only the shortest TAU isoform is present (0N3R), while 
during adulthood all six isoforms are found in the brain 50. Also, foetal forms of TAU promote 
assembly of microtubules less actively than adult forms, since it is in the inter-region between R1 
and R2 that relies the most potent part that induces microtubule polymerization. Notably this R1-
R2 inter-region is characteristic of adult TAU isoforms 4R, being responsible for the difference in 
the binding affinities between 3R and 4R TAU 52. 
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 Importantly, the alternative splicing of E10 is linked to different tauopathies according to 
the isoforms found in the protein aggregates, namely 4R tauopathies (comprising PSP, CBD and 
AGD), 3R tauopathies (such as PiD) and 3R+4R tauopathies, as exemplified by AD 53.   
 
 
 
Figure 4 – Schematic representation of the human MAPT gene and the six isoforms of the human brain. (Adapted 
from 54). 
 
 Domains and Structure of TAU 
Structurally TAU can be subdivided into two major domains: the Projection Domain (PD) 
and the Microtubule-Binding Domain (MiBD). The PD (N-terminal) encompasses a proline-rich 
region as well as an acidic region, and is so designated since it projects from the microtubule surface 
where it might interact with a neural plasma membrane, in addition to cytoskeletal elements such 
as spectrin and actin filaments, allowing for the interconnection between TAU-stabilized 
microtubules and neurofilaments that limit the flexibility of the microtubule grid. The PD is also 
important in the determination of the axonal diameter and spacing between microtubules in axons, 
and it is likely involved in signal transduction pathways concerning phospholipase C gamma (PLC-γ) 
50–52.  On the other hand, the MiBD interacts with microtubules through some repeated domains 
(R1-R4) located at the C-terminal, consisting of 18 amino acids encoded by exons 9, 10, 11 and 12, 
separated from each other by 13- or 14- residue spacer regions 55. The MiBD is extremely important, 
since it interacts with microtubules, allowing for their polymerization and stabilization, in addition 
to regulating their dynamic stability, being implicated in their normal function. Recent evidence 
also supports a role of the MiBD in the modulation of the phosphorylation state of TAU proteins, 
once it allows the competitive binding of microtubules to TAU, inhibiting Protein Phosphatase 2A 
(PP2A) activity 52.  
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 Subcellular localization and functions of TAU 
The distribution of TAU, at a subcellular level is adjusted according to the developing brain 
56, such that in the young neurons TAU is found among the cell body and neurites, while after the 
formation of axons and polarization of neurons, TAU is found in greater amounts in axons and 
depleted in dendrites and nuclei 57. For this reason, the presence of TAU in dendrites represents 
one of the first signs of neurodegeneration, although some studies suggest that its presence in such 
subcellular localization might be related to a role in the regulation of synaptic plasticity 54. This 
relocation of TAU might be due to several factors, namely the greater affinity of this protein to 
microtubules in axons than in dendrites 58 and the quick axonal transport of TAU right after its 
synthesis in the soma 59. Importantly, different isoforms of TAU are found in different cellular 
compartments of neurons, which can mean that the protein has specific features depending on 
their subcellular localization. This way disturbance of the distribution of these isoforms might 
induce a gain of function of TAU that becomes toxic, resulting in neurodegeneration 54. 
As previously stated, TAU has different functions according to its subcellular localization. 
Starting with axonal TAU, it is important to stabilize microtubules, leading to microtubule assembly 
and, more importantly, to regulate the dynamic instability of microtubules which facilitates the 
cytoskeleton reorganization 60. Another feature of TAU is the regulation of axonal transport of 
cellular components such as mitochondria or neurotransmitter vesicles by influencing the function 
of dynein and kinesin, responsible for the transport of cargoes towards the cell body (minus end) 
and towards the axonal terminus (plus end), respectively. An example of this regulation relies on 
the fact that TAU has a stronger inhibitory effect on kinesin than on dynein and, for this reason, in 
the soma of cells overexpressing TAU there is an accumulation of cargoes such as APP, which is 
carried by kinesin-vesicles along axons and dendrites. Also, TAU might affect the axonal transport 
of other cargoes through competitive binding to kinesin 61. In addition to this, TAU seems to be 
essential for axonal elongation and maturation, though such role still needs confirmation through 
further experiments 54. Besides the axon, it is believed that nuclear TAU is responsible for 
maintaining the integrity of genomic DNA, cytoplasmic RNA and nuclear RNA 62. 
Moreover, TAU may interact with actin, modifying the organization of the cytoskeleton 
network by inducing the alignment of bundles consisting of actin filaments 54.  
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 Post-translational modifications and implications in TAU function 
In tauopathies such as AD, the typically soluble TAU is present in an abnormal filamentous 
form, resulting from conformational changes and misfoldings in the normal structure of TAU, 
ultimately leading to the appearance of intraneuronal protein aggregates, thereby preventing the 
correct organization of the cytoskeleton 48.  The mechanisms responsible for TAU’s loss of function 
are not yet fully defined. However, like many proteins, TAU undergoes post-translational 
modifications, such as phosphorylation (hyperphosphorylation), acetylation, glycation, 
ubiquitination, nitration, truncation and some other modifications, which are believed to be the 
main cause of loss of normal function and acquisition of pathological features such as protein 
aggregation 63.  
Regarding the phosphorylation, the longest variant of TAU (2N4R) has 85 potential 
phosphorylation sites (45 serines, 35 threonines and 5 tyrosines) that are phosphorylated and/or 
dephosphorylated by multiple kinases or phosphatases, due to their easy accessibility resulting 
from TAU’s natively unfolded structure 54. Most of these potential sites are clustered in regions 
flanking the MiBD repeats (R1-R4), namely in the proline-rich region and in the C-terminal extreme, 
with the exception of Ser261 (R1), Ser285 (R1-R2 inter-repeat), Ser305 (R2-R3 inter-repeat), Ser 324 
(R3), Ser352 (R4) and Ser356 (R4) 52. Since phosphorylation plays a crucial role in regulating the 
physiological functions of TAU, such as the binding of TAU to microtubules and ultimately their 
stabilization and assembly, multiple studies have focused on the protein kinases and protein 
phosphatases responsible for the regulation of this microtubule-associated protein 54.  
The main kinases involved are the Glycogen Synthase Kinase 3β (GSK-3β), which is a 
serine/threonine protein kinase widely expressed in the brain and associated with microtubules 64; 
and Cyclin-Dependent Kinase 5 (CDK5), which is a serine/threonine protein kinase, member of the 
CDK family 65. Interestingly, CDK5-mediated phosphorylation leads to further phosphorylation of 
TAU by GSK-3β, favouring AD pathogenesis 66. This could be due to conformational changes that 
allow the access of GSK-3β as well as other kinases to further phosphorylate TAU 48,54. As for 
dephosphorylation of TAU, the phosphatases more likely involved are Protein Phosphatase 2A 
(PP2A), which accounts for ≈70% of the human brain TAU phosphatase activity 67, followed by and 
Protein Phosphatase 1 (PP1) . Studies show that the activity of PP2A is diminished in the brain of 
AD patients, which could result from post-translational modifications of its catalytic domain, 
reduced PP2A expression, as well as increased levels of endogenous PP2A inhibitors 68,69. 
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1.4 Genetics of AD 
As previously said, AD is a complex multifactorial dementia and, although our knowledge 
of the pathophysiology still remains in an initial state, it is broadly accepted by the scientific 
community that genes play a crucial role in both onset and development of the disease 70. 
To date, more than two hundred mutations have been linked to AD and every year more 
are discovered 10 .  Depending on the genetic cause and the age-of-onset, AD can be classified as 
Early-Onset Alzheimer Disease (EOAD) or Late-Onset Alzheimer Disease (LOAD). The latter is the 
most common type of AD 10,71,72. 
 
 
The EOAD tend to group within families, sometimes throughout generations 73. Usually it 
develops before the age of 65 years old and is transmitted as an autosomal dominant trait, caused 
by extremely penetrant mutations. Only about 5% of AD cases fit in this category. To date, three 
genes have been highly related to this type of AD: APP, PSEN1 and PSEN2 3,70,72 (Table 1). The first 
gene discovered was the APP gene, in 1987, which lies in the long arm of chromosome 21 74. Due 
to its location, patients who suffer from Down syndrome tend to develop AD later in life, as they 
have an extra copy of the APP gene2.  
The first missense mutation in APP was reported in 1991 75, after which nearly 20 other AD 
mutations have been reported in this gene. Most of the APP-variants take place close to the 
recognized -secretase site, between residues 714 and 717, suggesting that -secretase cleavage of 
APP is critical for AD development 70. A few years later, other mutation was linked to the 
development of EOAD. This mutation occurs on chromosome 14q24 and affects the PSEN1 gene, 
which encodes for presenilin 1 76, a highly conserved membrane protein necessary to release A 
from APP during the -secretase action. Every year new mutations are discovered to affect this 
gene. Subsequently mutations in PSEN2 (located in chromosome 1) were identified and associated 
with AD 70. These three genes are all involved in the production of A peptides, which gave rise to 
the Amyloid Hypothesis in the development of AD 72, whereby the pathophysiological process that 
ultimately result in the appearance of the neuropathological features of AD (SPs and NFTs), as well 
vascular damage and inflammation, are consequences resulting from the abnormal production of 
Aβ, rather than causes of the disease process 77. 
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Table 1 – Overview of the stablished EOAD genes and their functional relevance for AD pathogenesis. 
(Adapted from 72)  
Gene 
Chromosomal 
location 
Mode of 
inheritance 
Number of 
pathogenic 
mutations 
(affected families)a 
Relevance for ad 
pathogenesis 
APP 21q21.3 
Autosomal-
dominant 
51 (121) 
Increase in Aβ (Aβ42/Aβ40 
ratio); 
mutations close to γ-
secretase site 
PSEN1 14q24.3 
Autosomal-
dominant 
219 (480) 
Increase in Aβ (Aβ42/Aβ40 
ratio); 
essential for γ-secretase 
activity 
PSEN2 1q42.13 
Autosomal-
dominant 
16 (34) 
Increase in Aβ (Aβ42/Aβ40 
ratio); 
essential for γ-secretase 
activity 
a
(Source: “AD & FTD Mutation Database” [URL: http://www.molgen.ua.ac.be/ADMutations/] current on 6/10/2016) 
 
 
Most cases of AD are Late-Onset, representing about 95% of all cases 3, affecting people 
with 65 or more years of age. This type of AD is much more complex and less understood, both 
genetically and epigenetically, with the possible involvement of several genes. There can also be 
gene-gene and gene-environment interactions, which makes its appearance more unpredictable as 
the genes involved may contribute to or prevent the risk of developing the dementia, without 
causing it directly 71,73. 
Until recently only one gene had been associated with this form of AD. The gene encoding 
apolipoprotein E (APOE), located in chromosome 19, was linked to LOAD in 1993, after A was 
found to bind APOE 78. This association is due to the 4 allele of APOE, which has been consistently 
proved to be a risk factor of LOAD 3,72. However, studies have shown that APOE is limited to account 
for approximately 50% or less of LOAD risk 79, suggesting that other genes, and therefore other 
hazard loci, could contribute to LOAD risk . 
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In order to identify the remaining genes for LOAD, two methods have been suggested, 
namely Whole Exome Sequence (WES) and Genome-Wide Association Studies (GWAS) 19,80. The 
latter, allowed to overcome several technical limitations, due to the advent of microarray 
technology which makes it possible to evaluate several hundreds of thousands of Single-Nucleotide 
Polymorphisms (SNPs) in a single trial. Nevertheless, despite having several advantages once it is 
an approach hypothesis free, GWAS require more rigorous criteria to validate the significance of 
SNPs in a disease context 10. Also, since the effect sizes of the novel genes possibly related to AD 
are small, it requires a remarkably big number of individuals (cases and controls) in order to identify 
additional genes involved in LOAD, which represents another disadvantage of this method 81.  
Since 2009, and in addition to APOE, more than 20 loci have been identified by five GWAS 
and one meta-analysis, and significantly associated to LOAD. Among these are CLU, CR1, PICALM, 
BIN1, ABCA7, MEF2C, HLA-DRB1/HLA-DRB5, EPHA1, CD2AP, CD33, INPP5D, NME8, ZCWPW1, 
PTK2B, SORL1, CELF1, SLC24A4/RIN3, FERMT2 and CASS4 19,82–85. Depending on the possible role in 
the process of AD, these genes cluster in a specific set of pathways, namely Lipid Metabolism, 
Immune Response or else Endocytosis, strongly highlighting the relevance of these molecular 
mechanisms in AD aetiology 81,86. Of all these genes, and according to the Alzgene database 
(http://www.alzgene.org/), the bridging integrator 1 (BIN1) is currently recognised as the most 
significant LOAD-associated risk loci after APOE, and will be discussed in more detail in section 1.5.  
Despite all these advances and discoveries allowed by GWAS, a significant part of the 
genetic contribution to AD has not yet been explained and the APOE-4 allele remains the key gene 
variant considered to be a LOAD risk factor.  
 
1.4.2.1 APOE as a genetic risk factor for AD 
Apolipoprotein E (APOE) is a lipoprotein of 299 amino acids and 34kDa molecular weight, 
first discovered in 1970s as a protein component of triglyceride-rich lipoproteins 87.   
This protein has three major isoforms APOE2, APOE3 and APOE4 encoded by three alleles 
located on a single gene locus on position 19q13, being them 2, 3 and 4, respectively 88. The 
isoforms differ by a single-amino acid substitution at residues 112 and 158 (Figure 5), which 
provides structural changes that influence their functions both at a cellular and molecular level, 
allowing the association of different isoforms to different neuropathological conditions 89.  
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Figure 5 – Schematic representation of the structure of APOE. The different isoforms APOE2, APOE3 and 
APOE4 differ from one another at amino acid residues 112 and 158 (grey circles) providing unique features 
to each isoform. (Adapted from 90). 
 
Therefore, APOE3, which is the most common of the three isoforms and considered the 
normal form of APOE, has Cys-112 and Arg-158 91. On the other hand, APOE2 has Cys-112 and Cys-
158, the latter being responsible for greater stability of this isoform and associated with a protective 
effect against AD 92. Finally, the APOE4 which has Arg-112 and Arg-158, is a major risk factor for AD 
since the presence of one APOE-4 allele increases the risk to develop the dementia by about three 
times, while having two copies of the allele increases LOAD risk by 12 times 93 (Table 2). 
Furthermore, APOE-4 allele shifts the age of the disease onset, with each allele lowering the age 
of onset by one or two decades relative to non-carriers in LOAD 94.   
Importantly, while in EOAD mutations in the APP gene, the PSEN 1 gene or in the PSEN2 
gene are sufficient, but not required, to cause AD, the APOE-4 allele is neither indispensable nor 
necessary to cause AD, being considered a risk factor that diminishes the age of onset, as previously 
said 95.  
 
Table 2 – Comparison between APOE isoforms. Isoform-specific amino acid difference and allele 
frequency in each isoform for the general population and patients with Alzheimer’s Disease. (From 90) 
 Isoform-specific amino acid difference Allele frequency (%) 
112 158 General AD 
APOE2 Cys Cys 8.4 3.9 
APOE3 Cys Arg 77.9 59.4 
APOE4 Arg Arg 13.7 36.7 
 
 
 
112 158 
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Functionally, APOE usually is important for lipid metabolism as well as transport, and is a 
protein expressed in many organs, mainly in the liver followed by the brain. APOE occurs primarily 
as a constituent of lipoprotein complexes alongside with other apolipoproteins and proteins in 
plasma as well as cerebrospinal fluid (CSF) 96. In peripheral tissues, APOE is primarily produced by 
the liver and macrophages, being secreted into the circulation as a protein incorporated into very 
low-density lipoproteins (VLDL), chylomicron remnants, and certain subclasses of high-density 
lipoprotein (HDL) 86,89. APOE plays an essential role in the regulation of cholesterol as well as lipids 
throughout the organism facilitating the clearance of plasma lipoproteins through the low-density 
lipoprotein receptor (LDLR) as well as additional LDLR-related protein family members 87. In 
addition, in the central nervous system (CNS), this lipoprotein produced primarily by astrocytes 97,98,  
may be involved in several physiological and pathological processes, including the metabolism and 
trafficking of cholesterol, resulting from neurodegeneration, to neurons lacking them for 
membrane repair, proliferation or remyelinization 86. Despite neuronal trafficking, APOE also plays 
an essential role in synaptogenesis, blood-brain barrier integrity 97,98, and it affects glutamate 
receptor function and synaptic plasticity by modulating neuronal APOE receptor recycling 99. 
Although the mechanism by which APOE isoforms affect the risk to develop AD is not 
completely understood, significant evidence of diverse neuropathological effects of APOE4 on cells 
within the CNS have been validated. Decreased Aβ clearance 89 and increased Aβ aggregation 100,101 
has been demonstrated in 4 carriers, as well as Aβ load and plaque accumulation strongly 
correlated to APOE-4 dosage at autopsy 102,103. Finally, enhanced formation of C-terminal-
truncated fragments characteristic of 4 isoform stimulate TAU phosphorylation leading to 
preneurofibrillary tangles 104. 
It is important to keep in mind the fact that APOE has different influences in AD onset and 
progress according to the population ethnicity 105,106 and so it is extremely important to understand 
the relevance of this lipoprotein to each type of population since it might be useful for diagnosis 
purposes. 
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1.5 Bridging Integrator 1 (BIN1) 
BIN1, also named Amphiphysin2, is a member of the BIN1/amphiphysin/RVS167 (BAR) 
family of genes, encoding a nucleocytoplasmatic adaptor protein highly expressed in the CNS. BIN1 
maps to the long arm of the human chromosome 2 (2q14.3) and encodes no less than 20 exons 107, 
which can be spliced into several isoforms. Primarily, 19 exons were identified 108, after which an 
extra exon was discovered between exons 6 and 7, named exon 6a 109. 
 
 
In mammals BIN1 is widely expressed, but since BIN1 transcripts undergo an extensive 
differential splicing, more than 10 isoforms are produced with different subcellular localization, 
tissue distribution, and particular functions according to specific protein interactions. Furthermore, 
depending on the inclusion of four exons (6a, 10, 12 and 13) different types of isoforms are 
produced, including brain specific isoforms 1-7, muscle-specific isoform 8 and isoforms 9 and 10 
(ubiquitously expressed) 109. Also an aberrant isoform has been reported to be expressed 
specifically in tumour cells 108. Depending on the isoform expressed, BIN1 encodes proteins ranging 
from 409 amino acids (isoform 10) to 593 amino acids (isoform 1), having a predicted molecular 
weight of 45 kDa to 65 kDa, respectively. 
Relatively to BIN1 structure, it has numerous characteristic protein domains 110. The BAR 
domain (N-terminal) is ubiquitously expressed and binds lipid membranes in a dimer conformation, 
stimulating membrane curvature in places such as T-tubules in muscular cells, endocytic pits in 
neuronal and non-neuronal cells, and possibly in cytoplasmic endosomes 111,112. Importantly, the 
protein-protein interaction with dynamin can be modulated through differential splicing of exon 7 
in the BAR domain 113. In some brain isoforms there is also a N-terminal insert domain of 31 
residues, encoded by exon 6a, located within a putative coiled-coil region in the BAR domain 114. 
Another ubiquitously expressed domain is the Src Homology 3 (SH3) domain, which is 
encoded by exons 19 and 20 and allows the binding of proline-rich motifs 115. Interestingly, this 
domain in BIN1 differ from other SH3 domains owing to a large patch of negative electrostatic 
potential and a remarkably prolonged n-Src loop 116. The Myc-binding domain (MBD) is present in 
all isoforms, being encoded by exons 17 and 18 117, though alternative splicing of the first might 
lead to the loss of the interaction between BIN1 and c-Myc 108,118. Furthermore, exon 13 
differentially spliced in a tissue-independent manner, encodes part of the MBD 109. Between BAR 
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and MBD, in the muscle-specific isoform (isoform 8) exon 10 translates into a small domain of 15 
residues which includes a putative nuclear localization sequence (NLS), as well as a lipid-binding 
sequence 117,119. Finally, in brain-specific isoforms there is a clathrin and AP2 (CLAP) binding domain, 
which is encoded by exon 12 (including a series of alternative brain-specific exons 12A-D) and is 
responsible for binding to endocytic proteins, namely clathrin and AP2/α 120,121 (Figure 6).  
 
 
 
 
 
 
 
Figure 6 – Schematic representation of BIN1 domains and isoforms. Exons 6, 10, 12 (a-d) and 13 are alternatively 
spliced generating brain specific isoforms (1-7), a muscle isoform 8 and the two ubiquitously expressed isoforms (9 
and 10). Abbreviations: BAR, BIN1/Amphiphysin/RVS167 domain; CLAP, clathrin-AP2 binding region; MBD, Myc-
binding domain; SH3, Src homology domain; NLS, nuclear localization sequence. (Adapted from 109) 
 
 
The cellular functions performed by BIN1 are regulated through specific exon splicing, thus 
each isoform has a particular role in the organism, also depending on subcellular localization and 
tissue distribution. Furthermore, BIN1 may also be regulated by some post-translational 
modifications such as protein phosphorylation. Additionally, epigenetic processes, such as DNA 
methylation, might result in the inactivation and silencing of BIN1 by affecting the promoter 
activity, since it contains a CpG island 108. 
Several studies have associated BIN1 to the process of clathrin-mediated endocytosis as 
well as intracellular endosome trafficking both in neuronal and non-neuronal cells 107,122,123, through 
the interaction with numerous proteins, namely dynamin 122, AP2 adaptor complexes 122,123, clathrin 
121, synaptojanin 124, and endophilin 125, reflecting its ability to regulate membrane  remodelling. 
Furthermore, BIN1 has a potential role in regulating the actin cytoskeleton, coordinating 
membrane and cytoskeleton remodelling, given that it appears to link the two via the tubular 
membrane structure it forms. Thus, BIN1 might be involved in some AD neuropathological features 
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such as NFTs, since it might bind to the coiled-coil region of a plus-end protein involved in 
microtubules stability (CLIP170) though its BAR domain 110,126. Finally, BIN1 has numerous nuclear 
functions and has been associated to DNA repair, cell cycle and apoptosis 110. In fact, the MBD of 
BIN1 interacts with c-myelocytomatosis (c-MYC) oncoprotein, which has a crucial role in cell 
growth, apoptosis as well as malignancy 117, and several studies have shown that blocking BIN1 
expression or else BIN1-Myc interaction resulted in specific inhibition of Myc-mediated apoptosis 
127,128 .  It is important to note that only nuclear isoforms of BIN1 can activate apoptosis. Relative to 
DNA repair, BIN1, through the binding of its BAR domain to proteins which have a major role in this 
process, can modulate their activity 110.  
 
 
Since AD is such a multifactorial disease, recently several GWAS have been performed in 
order to identify risk loci involved in the pathogenesis of LOAD.  
After several studies, BIN1 has repeatedly been confirmed as a significant LOAD-associated 
risk loci, occupying the second position just after APOE 83,129–131. However, this locus was only 
considered statistical significant after the study performed by Seshadri et al. 129,being subsequently 
confirmed in other studies. From all the BIN1 Single Nucleotide Polymorphisms (SNPs) analysed, 
two were especially relevant for AD, being them rs7561528 and rs744373, both of which lie 
approximately 25kb to 30 kb upstream of the BIN1 gene, respectively. The first one has a risk allele 
“G”, while the second one has a risk allele “A” 109. Importantly, this work will be focusing on the SNP 
rs744373 since it has been correlated with the rate of cognitive decline and AD progression, in 
addition to its risk allele “G” being linked to faster Mini-Mental State Examination (MMSE) 
deterioration, though this outcome does not reach statistical significance 109.  
The significance of BIN1 as a risk loci to AD have been successfully replicated and confirmed 
in several independent candidate gene studies evaluating ethnically distinct populations, such as 
Caucasian and Caribbean Hispanic 132,133. Furthermore, the significance of BIN1 as a genetic risk 
locus to LOAD has been replicated and confirmed in the largest family-based GWAS 134, as well as 
in African American populations 135. However, this association was not detected in the Han Chinese 
136 nor the Korean population 137. Importantly, the most significant SNPs may vary from study to 
study, according to the datasets consisting of different ethnicities. 109 Besides, in a population, more 
than one SNP may be associated to AD, therefore more GWAS should be performed in order to 
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characterize, the best way possible, which SNPs contribute to AD in different populations. In 
addition, it is possible that the various SNP’s of BIN1 differentially affect the development of AD 
and, if this is true, it would be extremely interesting and useful to split subject groups and 
investigate the degree of cognitive decline separately for each BIN1 genotype 109. 
Some studies have analysed the expression of BIN1 in the human brain, detecting an 
increase of BIN1 transcripts in brains of AD cases when compared to controls 138. However, there 
are also studies that reveal a significant decrease of BIN1 in the brain of LOAD patients (87% when 
compared to non-demented age-matched controls) 139. In addition, although several SNPs of BIN1 
have been associated to LOAD, little is known about BIN1 protein expression and its contribution 
to AD pathogenesis. Thus it is imperative that more studies are performed in order to help clarify 
the role of BIN1 in AD pathogenesis, identifying in which pathways that genetic locus may be 
involved, and in which way that involvement contributes to the onset of AD or its progression. 
Since BIN1 has a role in the process of clathrin-mediated endocytosis, some studies have 
focused on the potential role of this BAR protein in APP metabolism and Aβ production, since they 
are both internalized through the endolysosomal trafficking pathway. Following this hypothesis, 
fluctuations on BIN1 expression would result in changes in APP trafficking through intracellular 
compartments, influencing whether APP undergoes the non-amyloidogenic or the amyloidogenic 
pathway, depending on the localization of the cleaving secretases. Thus, having been cleaved by β-
secretase in the endosomes, if APP moved into the cell surface it would be cleaved by α-secretase, 
however, if APP moved into lysosomes it would be cleaved by γ-secretase, giving raise to Aβ 140,141.  
Despite this, recent studies tried to investigate the importance of BIN1 in Aβ processing and 
secretion but failed to find any association between the levels of BIN1 and Aβ42  neurotoxicity 138. 
Also, another approach using siRNA to knockdown endogenous BIN1, and overexpressing BIN1 in 
SH-SY5Y cells failed to have an impact on APP processing 139.   
As mentioned previously, BIN1 has a potential role in regulating the actin cytoskeleton, 
coordinating membrane and cytoskeleton remodelling. Thus, it may interact with microtubule-
associated proteins, like TAU. To investigate this theory a recent study was performed and 
identified an association between BIN1 and TAU at a biochemical, genetic and neuropathological 
level, strongly suggesting that increased levels of BIN1 lead to an augmented AD risk by interacting 
with the TAU pathway, although the exact mechanism is still not clear. Some of the possibilities lie 
on the fact that previous studies show that BIN1 can stabilize T-tubule structure in muscles. Thus, 
BIN1 might modulate microtubule stability or else TAU phosphorylation/aggregation 138. Also, BIN1 
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might be involved in NFTs formation. However, although BIN1 and TAU colocalize, there has not 
been detected any colocalization between BIN1 and NFTs. This suggests that BIN1 can influence the 
early stages of AD, being a primary contributor to the disease through the promotion of TAU 
aggregation, rather than influencing the late stages of the TAU-related pathology when NFTs are 
formed. In addition, the knockdown of BIN1 resulted in the suppression of TAU-induced 
neurotoxicity 138. Despite these findings, a study had some contrasting results, showing no 
correlation between BIN1 and the amount of TAU pathology in AD 139. For this reason, more studies 
should be performed in other populations, in order to investigate the significance of BIN1 in AD 
pathogenesis, potentially through the TAU pathway. 
 
 
Besides AD, BIN1 has been associated to other diseases such as cancer, myopathies, namely 
centronuclear myopathy (CNM) and myotonic dystrophy (MD), and has also been linked to cardiac 
failure, though the latter requires more in-depth investigation 110. 
Starting with cancer, as stated above, BIN1 interacts with c-MYC and so it can inhibit MYC-
dependent transformation and tumour growth, as long as it is expressed at a standard level 117. 
Also, several studies have shown that the expression of BIN1 is reduced or altered in numerous 
cancer types, such as colon, prostate, breast and lung cancers, as well as hepatocarcinoma and 
neuroblastoma 142–145. Furthermore, a study was performed, and revealed that the decrease of BIN1 
expression leads to an increase of resistance to Cisplatin-based chemotherapy, which may be due 
to loss of control over the DNA repair mechanism 146.  Therefore, augmenting the expression of 
BIN1 might be an unusual and interesting strategy for the treatment of cisplatin-resistant cancers. 
Also, since BIN1 has been linked to cytoskeleton and membrane remodelling, it could be implicated 
in tumour cell migration and invasion, whereby its decrease would contribute to tumour 
progression. 
BIN1 is greatly expressed in the brain and skeletal muscles. In the latter, several studies 
have shown that BIN1 has a major physiological relevance, since the increase of its expression leads 
to myoblast fusion and differentiation, being also essential for the positioning and remodelling of 
T-tubules. This BAR protein might also be responsible for sarcomere organization, once again 
highlighting its importance to skeletal muscle 110.  Therefore, changes in BIN1 expression might 
result in diseases related to this type of tissue. 
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1.6 Diagnosis of AD 
The assessment of AD made by an individual’s primary care physician or neurologist, 
requires not only the presence of memory decline but also multiple cognitive deficits. The diagnosis 
criteria and guidelines for AD were first established in 1984 by the Alzheimer’s Association and the 
National Institute of Neurological Disorders and Stroke (AANINDS) 147 and last updated almost three 
decades later, in 2011, by the National Institute on Aging – Alzheimer’s Association (NIA-AA) 148. 
Usually the physician starts with the medical and family history of the patient, plus 
psychiatric history as well as behavioural, personality and cognitive changes. During this stage of 
the diagnosis it is extremely important to interview a family member or a friend close to the patient, 
since they may be useful to detect that something is wrong even before changes are evident on 
tests, and can even explain how cognitive abilities, practical skills and behaviours have changed 
over time 149. After the first assessment, the physician also performs neuropsychological tests, such 
as the Mini-mental state exam (MMSE), which allows the measurement of general cognitive 
function, with scores ranging from 0 (severe impairment) to 30 (no impairment), thus evaluating 
everyday mental skills.  
Due to the progress in radiological imaging techniques, Magnetic Resonance Imaging (MRI) 
and other neuroimaging techniques such as Computerized Tomography (CT) and Positron Emission 
Tomography (PET), these are being widely used for AD diagnosis 3. MRI exams are routinely 
requested, since they are three-dimensional, non-invasive and allow the characterization of the 
brain’s structure, just in a few minutes. There are several types of MRI, and some of the things that 
were possible to study using this technique go through the assessment of the integrity of white 
matter fiber tracts 150, to the study of local patterns of brain atrophy in individuals suffering from 
MCI and AD 30,151,152, and lastly the measurement of intrinsic brain activity, which takes place 
without any external stimulation, revealing changes in neuronal network activities in AD patients 
or individuals at risk for developing the dementia 153,154. MRI is very useful since it helps to rule out 
normal pressure hydrocephalus, brain tumours, cerebral hematomas or even cerebrovascular 
lesions 3. Another plus of this technique relies on the fact that it allows the detection of brain 
abnormalities in individuals who might be at risk to develop AD but have no apparent symptoms 
155. 
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Like MRI, PET has proven to be useful in the diagnosis of AD. Using 18F-fluorodeoxyglucose 
(FDG-PET) it was possible to differentiate between different forms of dementia, mainly AD and 
Frontotemporal Dementia (FTD), through the measurement of local brain metabolism 156,157. Recent 
advances certified the use of a radioactive compound named Pittsburgh compound B (PiB) during 
PET assessment of AD, since it binds specifically to amyloid plaques in the brain. That way it is 
possible to detect one of the neuropathological hallmarks of AD, in a non-invasive way. However, 
there are some concerns about the use of PET-based amyloid imaging in the clinical setting, notably 
due to its high cost and low positive predictive value 158. 
Another way of diagnosis that has been widely studied are the CSF-based protein 
biomarkers. Through these studies it was possible to discover that the levels of Aβ42 are reduced 
in AD patients, while the levels of phosphorylated TAU (P-TAU) are higher 159,160. Plasma biomarkers 
have also been suggested as an option to CSF biomarkers 161.  
Despite this, since AD is such a complex disease, innovative methods for AD biomarker 
identification as well as validation need to be established, in order to promote early AD diagnosis 
and therapeutic interventions 162. 
 
1.7 Treatment of AD 
Currently there is no cure for AD and scientists are just beginning to discover therapeutic 
methods that aid handling the symptoms of the dementia but do not delay the evolution or reverse 
the progress of the disease itself 163.  
Therapeutically AD presents no great difference from other dementias, using drugs based 
on transmitter-replacement therapies. Given that, in AD, as the initial affected neurons are the 
glutamatergic and acetylcholinergic, the first therapeutic approach is to administer 
Acetylcolinesterase inhibitors that will promote cholinergic neurotransmission by preventing the 
breakdown of acetylcholine, thus improving memory function and attention in AD patients. 
Currently there are three cholinesterase inhibitors approved by U.S. Food and Drug Administration 
(FDA). These are galantemine, donezepil and rivastigmine. Another FDA approved drug is 
memantine, an NMDA (glutamate) antagonist whose function is to prevent excessive glutaminergic 
transmission that may result in excitotoxicity because of high intracellular calcium concentration in 
circumstances of overstimulation 164. 
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Currently, growing evidences support the amyloidogenic hypothesis leading scientists to 
seek new therapeutic approaches in order to decrease the amount of Aβ in the brain. One class of 
such drugs are secretase inhibitors or modulators, thus preventing the processing of APP and 
production of Aβ 165. An alternative method is the use of inhibitors of amyloid aggregation or drugs 
that promote the clearance of Aβ. It is expected that this type of drugs is able to retard the progress 
of AD 166. 
Furthermore, as knowledge about the pathological mechanism underlying AD improves, 
additional therapeutic approaches are being studied namely drugs that target the abnormal TAU 
protein that originates the NFTs 167. 
Concerning the behavioural and emotional changes, typical in AD patients, there are some 
pharmacological options including antipsycotics, antidepressants or even anxiolytics, and some 
non-pharmacological approaches such as relaxation and physical exercise that should not be ruled 
out to help promote a better quality of life for the patient 164.  
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AD is the most common form of age-related dementia, being a complex multifactorial 
disorder in which genes play a crucial role in both onset and development of the disease. 
Most cases of AD are late-onset and, until recently, only the APOE gene had been associated 
to it. However, in the last few years through GWAS, BIN1 has been recognised as the most 
significant LOAD-associated risk loci after APOE, encoding a nucleocytoplasmatic adaptor protein 
highly expressed in the CNS. 
Although several SNPs of BIN1 have been associated to LOAD, two are especially relevant 
for AD, including rs744373. However, little is known about BIN1 protein expression and its 
contribution to AD pathogenesis. Thus, it becomes imperative to perform more studies in order to 
help clarify the role of BIN1 in AD pathogenesis. In addition, the most significant SNPs may vary 
from study to study, according to the datasets consisting of different ethnicities, whereby it is 
important to characterize, the best way possible, which SNPs might contribute to AD in different 
populations. 
 
The main goal of this thesis was to address if BIN1 polymorphism rs744373 can be 
considered a SNP that confers risk to the development of AD in a Portuguese population, specifically 
in the Aveiro district. Therefore, the particular aims of this work were to: 
 
 Amplify the polymorphic region of BIN1 gene (rs744373) by Polymerase Chain 
Reaction (PCR); 
 Determine the genotype of the study population through Sanger sequencing; 
 Determine the BIN1 (rs744373) genotypic and allelic frequencies in the pilot study 
group; 
 Evaluate the statistical significance of rs744373 as a risk factor to develop AD, in the 
study population; 
 Study the association of rs744373 with APOE-Ԑ4 carriers and CDR;  
 Study the association of rs744373 with Diabetes Mellitus. 
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3.1 Study Group 
The pilot study group was chosen from a cross-sectional population-based survey carried 
out at the University of Aveiro, which had the participation of 590 individuals from the Aveiro 
district. This set of individuals belonged to a primary cared based group (pcb-Cohort), of which 568 
were selected since they fulfilled the inclusion criteria (individuals aged 50 years or more). These 
568 individuals were assessed for their cognitive abilities, as well as the level of dementia. Thus, 
screening tests included Clinical Dementia Rate (CDR), Mini Mental State Examination (MMSE), 
Geriatric Depression Scale (GDS), Katz of Activities of Daily Living (ADL) and Instrumental Activities 
of Daily Living (IADL). All of these test were previously standardized for the Portuguese population, 
with the exception of ADL test 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Schematic diagram of the Study Design. A pilot study of 63 individuals (32 AD patients and 31 
Controls) was chosen for the work here described. 
 
 
 
251 subjects 
Excluded from 
this study 
Controls 
31 
AD patients 
32 
Study Population 
Viable blood sample 
590 subjects 
568 subjects 
508 subjects 
CDR 
CDR = 0 CDR = 0.5 CDR ≥ 1 
256 subjects 188 subjects 64 subjects 
MMSE - MMSE + 
32 subjects 
Age and gender-match control 
Inclusion/exclusion criteria 
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Of the 568 individuals that fulfilled the inclusion criteria, 60 were excluded for this study 
because they didn't have a viable blood sample, leaving 508 individuals. According to the cognitive 
evaluation and dementia screening performed in these individuals, for the present study we 
selected the ones which were CDR≥1 (64 individuals) and had a MMSE test positive for cognitive 
deficit, resulting in a total of 32 individuals considered as potential AD patients. Accordingly, 32 
individuals selected as AD patients, and 31 healthy control subjects (CDR = 0, and MMSE showing 
no cognitive deficits) matched for gender and age were chosen. The study design can be visualized 
in Figure 7. 
 
In summary, the study population consisted of 63 individuals, of which 31 were Controls 
and 32 potential AD patients. The latter group of individuals is herein referred to as AD patients. 
 
3.2 Ethical Approval 
The study from which AD patients and Controls were selected for the present work, was 
part of a project approved by the ethics committee for health of the Central Regional 
Administration in Coimbra (ARS) (Comissão de Ética para a Saúde da ARS Centro, protocol number 
012 804 of April 4, 2012), and by the National Committee for Data Protection (Comissão Nacional 
de Protecção de Dados). 
 Also, confidentiality of the data collected of each individual was assured. 
 
3.3 Sample Collection 
Blood samples were collected in 3 tubes (3mL for whole blood, 5mL for serum and 5mL for 
plasma) from each participant upon arrival, and placed in an EDTA tube, according to standard 
procedures, in order to prevent coagulation. As soon as the samples arrived at the laboratory, these 
were aliquoted right away and frozen at -80°C, being stored at iBiMED’s biobank. 
It is important to note that, despite having 568 individuals fulfilling the inclusion/exclusion 
criteria, only 508 blood samples were available. This was due to the fact that some individuals were 
quite old, making it difficult to collect blood samples. It was decided not to subject them to the 
procedure, in order not to cause any discomfort or pain to the volunteer. 
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3.4 BIN1 Genotyping 
BIN1 genotyping was performed resorting to the use of Polymerase Chain Reaction (PCR) 
technique, in order to amplify the selected SNP variant rs744373. Subsequent to amplification, PCR 
products were precipitated. In order to attest the successful amplification of the DNA fragments, 
samples were analysed through an agarose gel electrophoresis.  
 
 
PCR is a technique used to create multiple copies of a particular DNA sequence, using a DNA 
template. This way it is possible to yield enough DNA required for analysis. This technique was used 
to amplify the SNP rs744373 of BIN1 gene from the genomic DNA (gDNA) of each patient.  
There was no prior DNA extraction, since it was done directly by using Phusion Blood Direct 
PCR Master Mix (ThermoFisher Scientific, USA), according to the manufacturer’s instructions.  
Primers Forward (Fw) and Reverse (Rv) were design according to the scientific report of 
Darawi et al.168 and are shown in Table 3. 
 
Table 3 - Sequence of Primers Forward and Reverse for the genotyping of the polymorphism od BIN1. 
 
Gene SNP ID Primer Name Sequence (5’-3’) 
BIN1 rs744373 
BIN1-Fw AAG ACG GAG AGA GGA GGC AT 
BIN1-Rv CCA TCT TCT TCT GCT CTC CCA G 
 
Each PCR reaction was executed in a DNase free PCR microtube and the final volume of all 
PCR products was 20μL. The components of the reaction were added according to the order they 
are presented in Table 4. 
 
Table 4 - Components of the mixture used for PCR. 
 
Component of the Reaction Volume/Reaction (µL) 
Ultrapure H2O (DNase/RNase-free) 7μL 
Primer BIN1-Fw 1µL 
Primer BIN1-Rv 1µL 
2XPhusion Blood II DNA Polymerase Master Mix 10µL 
DNA template (sample) 1µL 
TOTAL 20µL 
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The PCR technique was performed resorting to the use of thermocycler Eppendorf® 
Mastercycler (Sigma-Aldrich, USA).  Cycle conditions for DNA amplification are indicated in Table 5. 
 
        Table 5 - Cycle conditions for the amplification of BIN1 polymorphism. 
 
Number of Cycles Temperature Time Stage of PCR 
1 98°C 5 min Initial denaturation 
35 
94°C 1 min Denaturation 
63°C 30 sec Annealing 
72°C 46sec Polymerization (extension) 
1 72°C 5 min Final extension 
- 4°C ∞ - 
 
 After DNA amplification, PCR products were centrifuged with Spectrafuge Mini Centrifuge 
(Labnet International, USA) at 1000×g (about 4000rpm) during 1 to 3 minutes in order to sediment 
all blood residues.  Following this step, samples were precipitated. 
 
 
After PCR products were centrifuged, 10µL of the supernadant were removed and placed 
in a new Eppendorf tube (1,5mL). All microtubes were previously identified with the sample 
number. In order to start the precipitation procedure 1µL of Sodium Acetate (3M, pH 5.2) was 
added to the solution, followed by 25µL of Ethanol 100%. Samples were stored at -20°C overnight. 
Afterwards, the samples were centrifuged at 14000rpm for 20minutes at 4⁰C. The 
supernatant was removed and 100μL of ethanol 70% were added to the remaining pellet. The 
samples were stored at -20°C for 20minutes, and later centrifuged at 14000rpm during 5minutes. 
The supernatant was removed, and the samples were then dried out completely at 37°C. Lastly, 
13μL of ultrapure H2O (DNase/RNase-free) was added to each tube in order to dissolve the 
remaining pellet. The purified DNA fragments were then kept at -20°C for long term storage and/or 
at 4°C for short term storage. 
 
 
 
Agarose gel electrophoresis is a technique used to separate DNA fragments of different 
sizes.  Depending on the concentration of agarose present in the gel it is possible to obtain larger 
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pores (less agarose) or smaller pores (more agarose). Generally, gels with higher concentrations of 
agarose (smaller pores) are used when the objective is to separate smaller fragments of DNA. Given 
that DNA is a negatively charged molecule, it migrates from cathode to anode by the porous matrix 
of agarose, through an electric field. The migration of nucleic acids occurs according to the fragment 
size, resulting in a faster and further migration by the shorter molecules. The concentration of 
agarose present on the gel needs to be carefully chosen, in order to allow the detection of the DNA 
band size of interest.  
Subsequently to precipitation of the PCR products, an agarose gel electrophoresis was 
executed in order to detect the specific band for rs744373 (767 bp). Thus, 130 mL of 1.5% agarose 
gels were prepared in 1x TAE buffer. The solution, heated until the agarose melted, was cooled 
down and 8µL of GreenSafe Premium® (Nzytech, Portugal) were added. The mixture was 
transferred into the gel tray and left to set for 25-35 min. For the gel run, the horizontal 
electrophoresis tank was filled with 1x TAE buffer. In order to prepare the DNA samples to be 
loaded, aliquots with 2µL gDNA of each sample were made, to which 0.4 µL of loading buffer (LB) 
was added to increase sample density and to add colour to the sample, facilitating loading and 
allowing to track the migration of samples. A 1Kb Plus DNA Ladder (ThermoFisher Scientific, USA) 
was used as a molecular weight marker. Gels run at 100V for 35 minutes and the purified DNA 
fragments were visualized under UV light and further analysed using the ImageLab 5.2.1 (Bio-Rad 
Laboratories, Inc., USA) software. 
 
 
Sanger sequencing is a method of DNA sequencing, widely used for smaller-scale projects, 
based on the selective incorporation of chain-terminating dideoxynucleotides (analogues of 
nucleotide bases) by DNA polymerase, thus chain elongation is terminated selectively at A, G, C or 
T.  Since these chain-terminating nucleotides lack 3'-hydroxyl group, further elongation of the chain 
is prevented. After ensuring the amplification of the DNA of interest (BIN1 polymorphism rs744373) 
by observing an agarose band with 767bp on gels, a 96-well plate was prepared in order to send for 
sequencing.  To each well 10µL of sample were added, prior to 3µL of Primer BIN1-Rv.  Afterwards 
the 96-well plate was sent to STABVIDA Sequencing Service (Portugal) for direct sequencing by the 
Sanger method. After obtaining the sequencing results from STABVIDA these were analysed in 
order to determine the nucleotide polymorphisms and the respective BIN1 genotype for each study 
individual. 
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Differences in gender and age as well as differences in genotype frequencies between AD 
patients and Controls were described using Pearson’s chi-square test and Cramer’s V for effect size. 
Differences in Minor Allele frequencies between AD Patients and Controls were assessed using 
Pearson’s chi-square test.  
The strength of association between rs744373 and AD was estimated with the odds ratio 
(OR) with 95% confidence interval (CI). The association between rs744373 and APOE or CDR was 
tested through Pearson’s chi-square test. An OR based on a bivariate analysis was performed to 
assess the association between rs744373 and Diabetes Mellitus, recurring to Pearson’s chi-square. 
P-values were calculated two-tailed and p-value<0.05 was defined as statistical significance. 
Statistical analysis was performed using SPSS 22.0 software (SPSS Inc; Chicago, IL).  
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4.1 Assessment of the balance between the two study groups 
The main goal of this work was to evaluate if BIN1 polymorphism rs744373 can be 
considered a SNP that confers risk to the development of AD in a group of 63 Portuguese individuals 
belonging to a population from a cross-sectional population-based study, in the Aveiro district.  
Since AD is a disease strongly associated with age and gender, usually affecting individuals 
older than 65 and female, an important aspect to take into account in such a study is to have a 
population that is balanced. Thus, we verified if both the AD patients group and the Controls group 
were similar for age and gender in order to avoid results that could be biased due to these two 
factors. 
In order to accomplish this, the first step was to run a statistical test to calculate the p-value 
and effect size (Cramer’s V) for both gender and age of the two study groups (Table 6).  With regard 
to gender, the number of men is the same in both groups and the number of women only differ in 
one individual, having a p-value of 0,932 and an effect size of 0,011. Regarding the age, when 
comparing the group of AD patients and the group of Controls we obtain a p-value of 0.550 and an 
effect size of 0,6. 
 
 
Table 6 - Comparison of gender and age between AD patients and Controls of the study population. 
 
AD patients  Controls p value 
Effect Size 
(Cramer’s V) 
Total sample (n) 32 31 - - 
Men [n (%)] 10 (69%) 10 (68%) 
0.932 0.011 
Women [n (%)] 22 (31%) 21 (32%) 
Age (Mean ± SD) 76.0 ± 9.0 77.4 ± 9.2 0.550 0.6 
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4.2 Amplification of BIN1 polymorphic region rs744373 by PCR 
After checking the homogeneity between the two study groups (AD patients and Controls), 
we proceeded to the amplification of the BIN1 polymorphic region rs744374 by PCR. There was no 
need to do prior extraction and quantification of genomic DNA since it was done directly by using 
Phusion Blood Direct PCR Master Mix (section 3.3.1).  
After amplification the PCR products were precipitated and results were visualized in 1.5% 
agarose gels. The expected fragment of 767 bp was obtained in all cases, being a prerequisite to 
send the samples for subsequent sequencing. An example of a gel obtained by agarose 
electrophoresis is this study can be observed in Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – BIN1 polymorphism region amplified by PCR technique. The product band has 767 bp and was 
visualized in 1.5% agarose gel. Samples 337, 412, 484 and 534 belong to AD patients while samples 315, 362, 
365 and 73 belong to Controls. 
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4.3 Correlating BIN1 polymorphism rs744373 with AD 
 
After completing the precipitation of the PCR products, samples were submitted to Sanger 
Sequencing (section 3.3.4) and were subsequently analysed. Accordingly, individual genotypes 
based on the sequencing patterns were obtained, and examples shown in Figure 9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Examples of Sanger-sequencing results of the BIN1 gene rs744373 polymorphism, of the study 
population. A - AA genotype, Homozygous non-risk carrier. B - GG genotype, Homozygous risk carrier. C – AG 
genotype, Heterozygous. 
A 
AA genotype, Homozygous non-risk carrier  
B 
C 
GG genotype, Homozygous risk-carrier 
AG genotype, Heterozygous 
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Note that, since the primer used for Sanger sequencing (introduced in the 96-well plate sent 
for sequencing) was the BIN1-Rv and not the primer BIN1-Fw, the sequencing results here presented 
are shown having a C nucleotide instead of a G, and a T nucleotide instead of an A. Despite this 
detail, during this work the genotype of the different individuals will always be referred to as AA, 
AG or GG. 
 
 
 
After being collected and properly analysed, the sequencing results were organized in a 
table, so that it was possible to perform their subsequent genotypic and allelic analysis. Results are 
shown in Table 7. 
 
Table 7 - Characterization of the study population according to gender, age and genotype.  
AD PATIENTS CONTROLS 
SAMPLE GENDER AGE GENOTYPE SAMPLE GENDER AGE GENOTYPE 
P1 F 56 AG C1 F 74 AA 
P2 F 74 AG C2 F 81 AG 
P3 F 83 AG C3 F 62 AG 
P4 M 74 AA C4 F 75 AG 
P5 F 70 AA C5 M 60 AG 
P6 M 74 AG C6 M 74 AA 
P7 F 78 AA C7 F 83 AA 
P8 F 77 AA C8 M 85 AA 
P9 M 88 AG C9 F 71 AA 
P10 F 73 AG C10 M 77 AG 
P11 F 85 AA C11 F 75 AA 
P12 F 78 AG C12 F 78 AG 
P13 M 81 AA C13 F 73 AG 
P14 F 78 AA C14 M 75 AG 
P15 F 95 AA C15 M 74 AA 
P16 F 75 AA C16 M 81 AA 
P17 M 78 AA C17 F 79 AG 
P18 F 82 AA C18 M 58 AG 
P19 F 84 AA C19 M 77 AG 
P20 F 91 AA C20 F 81 AA 
P21 F 86 AG C21 F 84 AG 
P22 M 87 AA C22 F 76 AA 
P23 F 88 AG C23 M 88 AG 
P24 F 76 AA C24 F 56 AA 
P25 F 80 GG C25 F 77 AA 
P26 F 80 AG C26 F 71 AA 
P27 M 60 AG C27 F 80 AA 
P28 M 58 AA C28 F 81 AG 
P29 F 71 AA C29 F 93 AA 
P30 F 62 AA C30 F 87 AG 
P31 M 79 AA C31 F 79 AG 
P32 M 75 AA     
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Analysing the results present in Table 7, one can conclude that the AD patients group has 
20 individuals with AA genotype (Homozygous non-risk carrier), 1 individual with GG genotype 
(Homozygous risk-carrier) and 11 individuals with AG genotype (Heterozygous, with 1 risk allele). 
On the other hand, the group of Controls shows 15 individuals with AA genotype and 16 with AG 
genotype, having no homozygous risk-carriers (GG genotype) (Table 8). 
 
Table 8 - Number of individuals with each genotype and genotypic frequencies within the different groups. 
GENOTYPE 
GROUP 
AD patients Controls AD patients + Controls 
Nº 
Individuals 
Genotypic 
Frequency 
Nº 
Individuals 
Genotypic 
Frequency 
Nº 
Individuals 
Genotypic 
Frequency 
AA 20 62.5% 15 48.4% 35 55.6% 
GG 1 3.1% 0 0.0% 1 1.6% 
AG 11 34.4% 16 51.6% 27 42.9% 
TOTAL 32 100% 31 100% 63 100% 
 
According to these results, we proccedeed to determine the genotypic frequencies of each 
genotype within the different groups. Comparing the two there are small differences among them 
(Table 8 and Figure 10). 
Starting with the AD patients group, the most frequent genotype was AA, having a 
genotypic frequence of 62,5%, followed by AG genotype (34,4%) and lastly GG genotype (3,1%). On 
the other hand, in the Controls group the genotype with higher genotypic frequence was AG 
(51,6%) followed by AA genotype (48,4%). In this group there were no individuals with the GG 
genotype. 
Considering all individuals (AD patients + Controls), 35 out of 63 present an AA genotype 
(corresponding to a genotypic frequence of 55,6%), 1 individual has a GG genotype (1,6%), and 27 
out of 63 individuals have AG genotype (42,9%). Thus, the order of the genotypic frequencies were: 
AA > AG > GG. 
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Figure 10 – Genotypic Frequencies in the different groups. 
 
 
Relatively to the allelic frequencies present in the different groups, in the AD patients 
group, allele A was the most frequent (51 alleles out of 64), while allele G represented only 13 
alleles out of 64. Also, in the Controls group the most frequent allele was A (46 allleles out of 62) 
and allele G was the less frequent (16 alleles out of 62). 
Therefore, when considering all individuals (AD patients + Controls), there is a big difference 
between the number of allele A and G present among the individuals, counting 97 alleles and 29 
alleles, respectively (Table 9). 
 
Table 9 - Number of each allele and allelic frequencies within the different groups. 
ALLELE 
GROUP 
AD patients Controls AD patients + Controls 
Nº Alleles 
Allelic 
Frequency 
Nº Alleles 
Allelic 
Frequency 
Nº Alleles 
Allelic 
Frequency 
A 51 79.7% 46 74.2% 97 77% 
G 13 20.3% 16 25.8% 29 23% 
TOTAL 64 100% 62 100% 126 100% 
 
After calculating allelic frequencies within the different groups, we can observe a big 
difference between the two alleles. Allele A has a higher frequency in both AD patients group and 
N = 32 N = 63 N = 31 
 
Genotypic Frequencies 
62.5% 
48.4% 55.6% 34.4% 
51.6% 
42.9% 
3.1% 
1.6% 
AD patients Controls AD patients + Controls 
N = 32 N = 31   3 
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Controls group, representing 79,7% and 74,2%, respectively. On the other hand, G allele has only 
an allelic frequency of 20,3% in the AD patients group and 25,8% in the Controls group. 
Looking for a global context, and considering all individuals, the allelic frequency of A allele 
is 77% against the 23% of the G allele (Figure 11). 
 
 
 
 
 
 
 
 
 
Figure 11 – Allelic Frequencies within different groups.  
 
 
One of the aims of this work was to evaluate the statistical significance of BIN1 
polymorphism rs744373 in the study population. Therefore, according to the genotypic frequencies 
present in the AD patients group and in the Controls group, the p-value and effect size were 
calculated in order to assess possible differences between the two groups. Thus it is possible to 
evaluate whether the genotype that confers higher risk for developing Alzheimer’s Disease (GG 
genotype) is present in a substantially greater quantity in AD patients than in Controls and, on the 
other hand, if the genotype that confers a lower risk of developing the disease (AA genotype) is 
higher in controls when compared to AD patients. If this scenario were to happen, it could mean 
that the analysed polymorphism constitutes a risk factor to developing AD, in the study population.  
N = 32 N = 63 N = 31 
 
Allelic Frequencies 
AD patients Controls AD patients + Controls 
79.7% 
74.2% 77% 
25.8% 23% 
20.3% 
A = 64 A = 62 A = 126 
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Comparing the AD patients group and the Controls group the p-value was 0.260 and the 
effect size was only 0,20 (Table 10), showing that the difference is not statistically significant 
between the two analysed groups. 
 
Table 10 - Comparison between the genotype of AD patients and Controls of the study population. 
 
AD patients  Controls p value 
Effect Size 
(Cramer’s V) 
Genotype (Nº 
Individuals) 
AA GG AG AA GG AG 
0.260 0.20 
20 1 11 15 0 16 
 
 
In order to assess if there were significant differences among the two groups and if the 
presence of the risk allele (also denominated Minor allele) of the BIN1 polymorphism rs744373 
(allele G) was significantly higher in the AD patients group rather than the Controls group, we 
performed an association test between the two groups (Table 11). With this test we intended to 
evaluate if the rs744373 could be considered as a risk locus to develop LOAD, in this particular 
population. 
 
            Table 11 - Association of rs744373 with the AD risk in the study population. 
 Number of individuals MAF Association test 
 
AD 
patients 
Controls 
AD 
patients 
Controls OR(95% CI) p-value 
rs744373 32 31 0.203 0.258 
0.733 
(0.318–
1.686) 
0.464 
              Key: MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. 
 
Comparing the AD patients group and the Controls group we didn’t find strong evidence of 
association for rs744373 with the AD risk (odds ratio [OR] = 0.733 , p-value = 0.464). 
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One of the goals of this work was to assess if there was an association between APOE-Ԑ4 
carriers and BIN1 polymorphism rs744373 as well as an association between rs744373 and CDR 
(Table 12). 
Overall, we can observe that, in the first situation, most of the study subjects are non-Ԑ4 
carriers (84.1%). Of those, 31 have an AA genotype, 21 have an AG genotype and only one has a GG 
genotype. On the other hand, Ԑ4 carriers count for 10 out of 63 of the total study population. Of 
those, 4 have an AA genotype and 6 have an AG genotype, but none with respect to the main risk 
genotype (GG).  
No statistical significance was detected between rs744373 and APOE-Ԑ4 carriers (p-value = 
0.467).  
 
Table 12 - Association of rs744373 with APOE-Ԑ4 (carriers and non-carriers) and CDR in the study 
population. 
 
SNP Genotype 
APOE-Ԑ4 
Association 
test 
CDR 
Association 
test 
Non-Ԑ4 
carriers 
Ԑ4 
carriers 
p-value 
CDR=0 
Normal 
CDR≥1 
Dementia 
p-value 
rs744373 
AA 
 [n/n total 
AA 
genotype 
(%)] 
31/35 
(88.6%) 
4/35 
(11.4%) 
0.467 
15/35 
(42.9%) 
20/35 
(57.1%) 
0.269 
AG 
 [n/n total 
AG 
genotype 
(%)] 
21/27 
(77.8%) 
6/27 
(22.2%) 
16/27 
(59.3%) 
11/27 
(40.7%) 
GG  
[n/n total 
GG 
genotype 
(%)] 
1/1 
(100%) 
0/1  
(0.0%) 
0/1 
(0.0%) 
1/1 
(100%) 
Total/ 
Total 
study 
population 
53/63 
(84.1%) 
10/63 
(15.9%) 
- 
31/63 
(49.2%) 
32/63 
(50.8%) 
- 
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Relative to the correlation between rs744373 and CDR, the number of normal individuals 
(CDR=0) and individuals with dementia (CDR≥1) are very similar (31 against 32, respectively). In the 
group of CDR=0, 15 have an AA genotype and 16 have an AG genotype. In this group there are none 
homozygous risk-carrier (GG genotype). On the other hand, in individuals with dementia (CDR≥1), 
20 have an AA genotype, 11 have an AG genotype, and only one has a GG genotype.  
No statistical significance was detected between rs744373 and dementia (CDR≥1) (p-value 
= 0.269).  
 
 
Since AD is such a multifactorial disease, we wanted to evaluate if the polymorphism 
studied in this work was related to some comorbidities such as Diabetes Mellitus, hypertension and 
gastrointestinal disease. Of these only the first showed an association with rs744373 (Table 13) and 
so, the results for other comorbidities are not presented in this work. 
 
Table 13 - Association of rs744373 with Diabetes Mellitus in the study population. 
SNP Genotype 
Diabetes Mellitus Association test 
No Yes p-value OR (95% CI) 
rs744373 
AA 
 [n/n total AA genotype (%)] 
33/35 
(94.3%) 
2/35 
(5.7%) 
0.035 6.60 (1.27-34.23) 
AG 
 [n/n total AG genotype (%)] 
19/27 
(70.4%) 
8/27 
(29.6%) 
GG  
[n/n total GG genotype (%)] 
1/1 (100%) 
0/1  
(0.0%) 
Total/ Total study 
population 
53/63 
(84.1%) 
10/63 
(15.9%) 
- - 
 
In the study population, Diabetes Mellitus was present in 10 individuals and absent in 53. 
Most of the subjects which had Diabetes present AG genotype and only 2 had an AA genotype. On 
the other hand, in individuals without Diabetes, AA genotype was the most frequent, followed by 
AG genotype. The main risk genotype (GG) was only present in 1 individual, which had no Diabetes.  
A significant association between rs744373 and dementia Diabetes Mellitus (odds ratio 
[OR] = 6.60, p-value = 0.035) was detected. 
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In the last few years, with the world’s population rapidly aging, and with the extended life 
spans, Dementia is becoming increasingly common, representing one of the major factors driving 
of costs in the health care and social systems, thus being a major health and socio-economic 
problem worldwide. Although there are several types of dementia, AD is the most common and for 
this reason, it becomes increasingly imperative to understand the genetic and molecular 
characteristics associated with the disease, so that it is possible to establish early diagnostic 
methods and to develop therapeutic strategies that allow to delay its progression. In addition, till 
present the definite diagnosis of AD is only possible by neuropathological examination at autopsy 
or biopsy and so there is a lot of pressure to find new ways to diagnose AD based on biomarkers 
and genetic tests. Over the years, several studies have focused on finding answers to these 
problems, however a lot questions still remain 169,170. Also, since AD is such a multifactorial disease, 
understanding the interactions among genetic, epigenetic and environmental factors and pathways 
that might be linked can provide useful information concerning ways of controlling this dementia 
5,15. 
Regarding the genetics of AD, recently BIN1 has been recognised as the most significant LOAD-
associated risk loci after APOE. Several functions have been described for BIN1, such as a role in the 
process of clathrin-mediated endocytosis as well as in regulating the actin cytoskeleton 107 leading 
to many possible associations of this protein to rare and common diseases affecting different 
tissues and physiological functions 110. Relative to AD, several studies evaluated the potential role 
of this BAR protein in APP metabolism and Aβ production but failed to find any association between 
the levels of BIN1 and APP processing 139 or Aβ42 neurotoxicity 138. Further, BIN1 have been 
associated with TAU pathology, since it might modulate microtubule stability or else TAU 
phosphorylation/aggregation 138, influencing the early stages of AD. However, these findings are 
not completely accepted by the scientific community and so, further studies should focus on 
answering some of these questions. 
Moreover, several GWAS have been performed by several groups and although many SNPs of 
BIN1 have been linked to LOAD, little is known about BIN1 protein expression and its contribution 
to AD pathogenesis. Among those, rs744373 SNP (risk allele G) was one of BIN1 polymorphisms 
that was especially relevant for AD 109,129. Nevertheless, it was still not possible to draw conclusions 
about the significance of this polymorphism in different types of populations and the number of 
individuals that has been analysed is small to achieve this level of significance. Thus it is imperative 
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that more studies are performed in order to help clarify the importance of BIN1 to LOAD in different 
groups of individuals with different ethnicities. 
 In this perspective and since, to our knowledge, no studies have been done in order to assess 
the relevance of BIN1 polymorphism rs744373 as a risk locus for AD, in a Portuguese population, 
the work here presented aimed to investigate the BIN1 profile, related to rs744373, in a pilot study 
group of 63 individuals (32 potential AD patients and 31 controls) from a cross-sectional population-
based study on a Portuguese population, in the Aveiro district. 
 
5.1 Assessment of the balance between the two study groups 
Since AD is a multifactorial disease which usually affects people over 65 years old and 
predominantly female, in this type of study it is important to evaluate if the groups to be studied 
are balanced, particularly regarding both gender and age, so the results are not influenced by 
significant differences between the two groups with respect to these two factors. The individuals 
of the study were divided into two groups: AD patients and Controls. The first group had 22 females 
and 10 males, while the second has 21 females and 10 males (p value = 0.932 ; effect size = 0.011). 
The mean age of AD patients was 76 years and in Controls it was around 74 years (p value = 0.550 
; effect size = 0.6). According to these results, we can conclude that there are no significant 
differences between the two study groups, therefore it is a balanced population. Note that, since 
BIN1 is believed to be associated with LOAD 129 and not to EOAD, we were careful to try to select 
individuals aged over 65 years old. 
 
5.2 Determination of BIN1 polymorphism rs744373 genotypic frequencies 
in the study population 
In order to amplify BIN1 polymorphic region rs744373, PCR reactions were carried out. After 
this was performed a precipitation of the PCR products which were later subjected to Sanger 
sequencing. Genotypic and allelic frequencies of rs744373 SNP were determined for AD patients 
and Controls, as well as the genotypic and allelic frequencies for all study subjects. Considering the 
AD patients group, the genotype frequencies were as follows: AA > AG > GG, with 62,5%, 34,4% and 
3,1%, respectively. The results of the Control group were slightly different, with the highest 
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genotypic frequency corresponding to AG (51,6%), followed by AA (48,4%). The GG genotype was 
absent in this group. Overall, considering all individuals of the study, the most frequent genotype 
was AA and this was found to be 35 times higher than the less frequent genotype, which was GG. 
This results lead us to believe that BIN1 polymorphism is not a risk factor for this specific Portuguese 
population, since the non-risk genotype (AA genotype) is present in most of the individuals in the 
study, while the genotype which confers the greater risk (GG genotype) is only present in one 
individual in both groups (found in 1 AD patient). 
 
5.3 Determination of BIN1 polymorphism rs744373 allelic frequencies in 
the study population 
Regarding the rs744373 SNP allelic frequencies, we can observe a major difference between 
the A allele and the G allele, being that the first has an overall allelic frequency of 77%, while G 
allele has an allelic frequency of only 23%. Thus, in this study population, the A allele is 3 times 
more frequent than allele G. Looking at the two study groups separately, one can observe that the 
results are very similar between the groups (79,7% AA and 20,3% GG in AD patients, against 74,2% 
AA and 25,8% GG in Controls). Once again, these results emphasize the low presence of the risk 
allele G in this study population, besides showing that differences between groups are not very 
evident, indicating that the BIN1 polymorphism rs744373 is not relevant for the onset and 
development of LOAD, for this particular set of individuals. 
 
5.4 Evaluation of the statistical significance of rs744373 in the study 
population 
Subsequently the statistical significance of rs744373 in the study population was evaluated. 
First it was found that there are no significant differences among genotypes between the two study 
groups (p-value = 0.260, Cramer’s V = 0,20). In addition, the results do not seem too promising since 
we did not find strong evidence of association for rs744373 with the AD risk (odds ratio [OR] = 0.733 
, p-value = 0.464). When consulting the literature (Table 14), it is evident that these results are 
consistent with studies previously performed in different populations such as the Finish 
population132, the African American135 and the Han Chinese population 136, which suggest that BIN1 
is not necessarily associated with AD development. Despite this, although our study failed to do so, 
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other studies were able to replicate the results of Seshadri et al., which was the first group providing 
compelling evidence that the polymorphism rs744373 is associated to LOAD (p value = 1.59x10-11), 
identifying BIN1 as a risk factor for AD. Moreover, studies performed in Spanish populations and in 
an Italian population found strong evidence of the association between BIN1 (rs744374) and an 
augmented risk of developing AD. In fact, a study performed by J.-C. Lambert et al. showed that, 
regardless of having two significant associations (Spanish and Italian populations) and a not 
significant result (Finish population), overall, when performing a meta-analysis, there was a high 
significance of BIN1 polymorphism rs744373 to AD (p-value = 2.9x10-7). Once again, these results 
emphasize the need to carry out more of these studies, since only one study in each population 
proves to be insufficient to draw conclusions about the significance of a gene with respect to the 
onset or development of AD.   
  
Table 14: Association of BIN1 polymorphism rs744373 with AD in different study populations. 
SNP 
Minor 
Allele 
Population 
No. Subjects 
MAF 
Association Test 
Ref. 
Cases Controls p-value OR(95% CI) 
rs744373 G 
Causasian 8371 26969 0.29 1.59x10-11 1.15 (1.11-1.20) 129 
Spanish 1140 1209 0.29 0.020 1.17 (1.03-1.33 129 
Spanish 726 829 0.29 1.4x10-7 1.43(1.22-1.68) 132 
Italian 1460 1265 0.29 0.002 1.22 (1.07-1.38) 132 
Finish 563 529 0.24 0.260 1.12 (0.92-1.37) 132 
African 
American 
513 496 0.48 0.999 1.00 (0.84-1.20) 135 
Han 
Chinese 
612 612 0.35 0.217 1.11 (0.940-1.312) 136 
Portuguese 32 31 0.23 0.464 0.733 (0.318-1.686) 
This 
study 
Key: MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; Ref, Bibliographic reference. 
 
In this work we failed to confirm the association of BIN1 polymorphism rs744373 with AD risk. 
However, the lack of replication of the results obtained by Seshadri et al. might be due to the small 
sample size, when compared to other consortium-based GWAS. Also, with such a small population 
this study turns out to have no power to detect rare variants with weak effects. Furthermore, the 
absence of replication of the original findings could be due to type I error (ie, false-positive results 
in the original study). Despite this conclusion, it would be extremely interesting and relevant to find 
an association between BIN1 polymorphism rs744373 and AD with such a small population size 
since, if we had found an association between the two, we could hypothesize that this SNP could 
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be used for diagnosis purposes, since a simple genetic analysis of this locus could determine the 
propensity of an individual to develop AD. 
Despite the small size of our sample, other studies performed in larger samples also reached 
the conclusion that rs744373 is not relevant to AD, which may confirm that SNPs which confer risk 
to onset and development of AD are specific to each population. With our results, rs744373 would 
not be specific for the Portuguese population, although other SNPs could contribute to AD risk. For 
this reason, it is imperative to reproduce this study in a larger population, as well as investigate the 
possible association of other polymorphisms of BIN1 in the Portuguese population, in order to 
better understand the genetic behind AD. 
 Still, there may be another reason to justify the lack of significance of this polymorphism in 
our study population. According to B. Jiao et al. the SNP rs744373 (allele A) might have a protective 
effect against AD in a Chinese population 171. Nevertheless, this is still poorly explored and so, 
according to the lack of significance in our results for the Portuguese population, it might be 
possible that in these specific individuals rs744373 exerts a protective effect, however additional 
studies in larger Portuguese populations are required to determine if this can be a likely 
explanation. 
Importantly, despite the results and literature herein presented (Table 14), it is important to 
have in mind that these results do not mean that BIN1 has no association with AD. In fact, several 
other SNPs in this candidate gene, identified from previous GWAS, have been linked to the disease. 
An example can be found in the study performed by Logue et al., which revealed that, despite 
rs744373 not having an association with AD in African Americans, in the same study population 
rs11685593, rs11691237 and rs7585314 were significant with a p-value of 0.0098 to the first two 
SNPs and a p-value of 0.003 to the latter 135. This highlights that the most significant SNPs may vary 
within different populations and that more than one SNP may be associated to the development of 
AD, emphasizing the importance of continuing to perform further studies of this nature in more 
types of populations, and even in populations which have already been analyzed, by increasing the 
number of SNPs to be analyzed in each population. Also, the greatness of the effect of a risk allele 
may differ among populations since gene-gene or gene-environment interactions may be exerting 
an effect in the study individuals and so future studies should continue to assess possible 
interactions between SNPs. 
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5.5 Association of rs744373 with APOE-Ԑ4 carriers and CDR 
Another goal of the current work was to identify whether rs744373 was associated with 
APOE-Ԑ4 allele or CDR≥1, in our study population. We first analyzed the association between the 
polymorphism and APOE-Ԑ4 carriers. However, no association was detected (p-value = 0.467). Since 
BIN1 as a role in clathrin-mediated endocytosis and in intracellular endosome trafficking, it would 
be expected to be associated with APOE. Despite this, our results show otherwise. Nevertheless, 
just because rs744373 does not appear to be related to the risk allele of that apolipoprotein, it does 
not mean that BIN1 has no association, since other SNPs may be associated to that protein. 
Therefore, more studies should be done in order to evaluate if BIN1 interacts with APOE, resulting 
in a higher probability of developing AD. 
Relatively to CDR, we wanted to analyse if, in our study population, subjects with dementia 
had a greater chance of having the presence of the risk allele of rs744373 (G allele). If we would 
have found that association, it would be an asset for diagnosis purposes, since the detection of the 
risk allele in an individual could mean that this person was more likely to develop dementia in the 
future. However, the current study did not detect an association between CDR≥1 individuals and 
rs744373 risk allele (p-value = 0.269). Nevertheless, as described above, the lack of association 
found in our results could be due to sample size, which was not large enough to detect extremely 
weak interactions. 
 
 
5.6 Association of rs744373 with Diabetes Mellitus 
The last goal of this work was to study the association of the gene variant rs744373 with 
Diabetes Mellitus (DM). AD is a multifactorial disease, affected by genetic, epigenetic and 
environmental factors. As previously stated, some of the non-genetic factors that might contribute 
to AD include infections, hormones or even Diabetes 16.   
In addition, studies suggest that the increased familial risk in African Americans is probably a 
result of higher rates of risk factors, including poor education, DM, and smoking 135. Our results are 
consistent with this literature, since rs744373 risk allele seems to be associated with the presence 
of DM (odds ratio [OR] = 6.60, p-value = 0.035). Thus, in this study population, individuals with 
diabetes are 6.60 times more likely to have the risk allele of BIN1 polymorphism (G allele) and, 
therefore more likely to develop AD. A follow-up study, in a larger population should be addressed, 
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in order to investigate if these results can be generalized to the Portuguese population, or if they 
are limited to our study population. 
 
 
5.7 Final conclusions 
Although this study represents an important step in elucidating the genetic basis of AD in a 
Portuguese population, and offers some understanding for population-specific genetic risk factors, 
it has some restrictions. First, the small sample size of this study may be underpowered to detect 
the small effects of this BIN1 polymorphism (rs744373) on AD risk. Likewise, since it was beyond 
the scope of this study, we did not study gene-gene or gene-environment interactions, which would 
be an asset.  
Most association studies have focused on a single population in order to decrease genetic 
background noise and reduce the likelihood of false-positive findings. For this reason, validation in 
additional populations is mandatory to conclude the generalizability of the contribution of BIN1 
gene to AD risk and the possibility of population-specific causative variants. 
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CONCLUDING REMARKS: 
 Of the three possible genotypes for BIN1 polymorphism rs744373, in the AD patients 
group AA genotype had highest frequency, while in Controls group the most frequent 
genotype was AG. 
 
 In both study groups GG genotype was the one with the lowest frequency. 
 
 In our study population A allele is 3 times more frequent than allele G (risk allele), 
indicating that rs744373 doesn’t confer risk to AD. 
 
 We did not find strong evidence of association for rs744373 with the AD risk (odds 
ratio [OR] = 0.733 , p-value = 0.464), in agreement with other studies. This supports 
the fact that it is important to carry out a follow up study to clarify these results. 
 
 In our study population the most significant SNP may be a SNP other than rs744373, 
associated to the development of AD. To answer this, further studies are required. 
 
 We did not detect an association between rs744373 and APOE-Ԑ4 carriers or CDR≥1 
individuals. 
 
 An association between rs744373 risk allele and the presence of DM was evident. 
Nevertheless, due to our small sample size a follow-up study in a larger sample should 
be performed to evaluate if these results can be generalized to the Portuguese 
population. 
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This section presents the reagents as well as the equipment necessary for the several 
techniques used during this work. 
 
7.1 Polymerase Chain Reaction (PCR)  
EQUIPMENT 
 Thermocycler Eppendorf® Mastercycler (Sigma-Aldrich, USA) 
 Spectrafuge Mini Centrifuge (Labnet International, USA) 
REAGENTS 
 2XPhusion Blood Direct PCR Master Mix (ThermoFisher Scientific, USA) 
 Primers (Eurogentec, Belgium) 
o BIN1-Fw: 5’ AAG ACG GAG AGA GGA GGC AT 3’ 
o BIN1-Rv: 5’ CCA TCT TCT TCT GCT CTC CCA G 3’ 
 Ultrapure DNase/RNase-free distilled H2O (ThermoFisher Scientific, USA) 
 
7.2 Precipitation of DNA fragments 
EQUIPMENT 
 5417R Mini centrifuge (Eppendorf AG, Hamburg) 
REAGENTS 
 Sodium Acetate (pH 3M, pH 5.2)  
To 80mL of deionized H2O add: 
- 24,6g Sodium Acetate, minimum 99,0% (Sigma-Aldrich, USA) 
Mix until the solute has dissolved and adjust pH to 5.2 with Glacial 
Acetic Acid. 
Adjust the volume to 100mL with deionized H2O. Store at room 
temperature. 
 
 Ethanol 100% (Aga, Portugal) 
 Ethanol 70% (Aga, Portugal) 
 Ultrapure DNase/RNase-free distilled H2O (ThermoFisher Scientific, USA) 
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7.3 Agarose Gel Electrophoresis 
EQUIPMENT 
 DNA electrophoresis system (Bio-Rad Laboratories, Inc., USA) 
 PowerPACTM Basic 300V (Bio-Rad Laboratories, Inc., USA) 
 Molecular Imager® Gel DocTM XR+ (Bio-Rad Laboratories, Inc., USA) 
REAGENTS 
 Agarose (Nzytech, Portugal) 
 Bromophenol Blue 
To 7mL of deionized H2O add: 
- 0,025g bromophenol blue (0,25%) 
- 3mL glycerol (30%) 
Mix and store at 4°C. 
 
 Greensafe (Nzytech, Portugal) 
 0,5M Ethylenediamine tetra-acetic  acid (EDTA) (pH 8.0) 
To 80mL of deionized H2O add: 
- 14,612g EDTA 
Mix until the solute has dissolved and adjust pH to 8.0 with NaOH. 
Adjust the volume to 100mL with deionized H2O. Store at room 
temperature. 
 
 50X TAE (Tris-Acetate-EDTA Buffer) 
To 600mL of deionized H2O add: 
- 242g Tris Base 
- 57,1mL Glacial Acetic Acid 
- 100mL 0,5M EDTA (pH 8.0) 
Mix until the solutes have dissolved and adjust the volume to 1L with 
deionized H2O. Store at room temperature. 
 
 1kb Plus DNA Ladder (ThermoFisher Scientific, USA) 
 
